Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.
复制标题
DOI：
10.1007/s12072-015-9675-4
复制
发表时间：
2016-01
影响因子：
6.6
通讯作者：
Kao JH
中科院分区：
文献类型：
--
作者：
Sarin SK;Kumar M;Lau GK;Abbas Z;Chan HL;Chen CJ;Chen DS;Chen HL;Chen PJ;Chien RN;Dokmeci AK;Gane E;Hou JL;Jafri W;Jia J;Kim JH;Lai CL;Lee HC;Lim SG;Liu CJ;Locarnini S;Al Mahtab M;Mohamed R;Omata M;Park J;Piratvisuth T;Sharma BC;Sollano J;Wang FS;Wei L;Yuen MF;Zheng SS;Kao JH
全球约有 2.4 亿人患有慢性乙型肝炎病毒 (HBV)，其中非洲和亚洲的感染率最高。我们对乙型肝炎病毒感染的自然史以及由此产生的疾病的治疗潜力的了解正在不断提高。自 2012 年发布之前的 APASL HBV 感染管理指南以来，已经有了新的数据。本手稿的目的是更新慢性 HBV 感染最佳管理的建议。 2015 年指南是由 APASL 选出的亚洲专家小组制定的。临床实践指南基于现有出版物的证据，如果没有证据，则基于专家的个人经验和审议后的意见。截至 2015 年 1 月发表的重要会议的手稿和摘要均已接受评估。该指南涵盖了乙型肝炎感染患者的全方位护理，包括新术语、自然史、筛查、疫苗接种、咨询、诊断、肝病阶段评估、单种或联合抗病毒药物的适应症、时机、选择和持续时间、HCC筛查、特殊情况下的管理，如儿童、妊娠、合并感染、肾功能损害以及肝病前期和后期。 移植和政策指南。然而，不确定性领域仍然存在，因此临床医生、患者和公共卫生当局必须继续根据不断变化的证据做出选择。这里介绍了最终的临床实践指南和建议以及相关的背景信息。
Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection and the potential for therapy of the resultant disease is continuously improving. New data have become available since the previous APASL guidelines for management of HBV infection were published in 2012. The objective of this manuscript is to update the recommendations for the optimal management of chronic HBV infection. The 2015 guidelines were developed by a panel of Asian experts chosen by the APASL. The clinical practice guidelines are based on evidence from existing publications or, if evidence was unavailable, on the experts’ personal experience and opinion after deliberations. Manuscripts and abstracts of important meetings published through January 2015 have been evaluated. This guideline covers the full spectrum of care of patients infected with hepatitis B, including new terminology, natural history, screening, vaccination, counseling, diagnosis, assessment of the stage of liver disease, the indications, timing, choice and duration of single or combination of antiviral drugs, screening for HCC, management in special situations like childhood, pregnancy, coinfections, renal impairment and pre- and post-liver transplant, and policy guidelines. However, areas of uncertainty still exist, and clinicians, patients, and public health authorities must therefore continue to make choices on the basis of the evolving evidence. The final clinical practice guidelines and recommendations are presented here, along with the relevant background information.
影响因子：
3.4
作者：
Choung BS;Kim IH;Jeon BJ;Lee S;Kim SH;Kim SW;Lee SO;Lee ST;Kim DG
通讯作者：
Kim DG